Immix Biopharma – executive interview

Immix Biopharma – executive interview

Immix Biopharma — 2 videos in collection

More on this equity

Immix Biopharma is developing a new class of tissue-specific therapeutics (TSTx) targeting oncology and immune-dysregulated disease. In Q422, the company’s lead clinical asset, IMX-110, is expected to begin a Phase IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumours in combination with the ICI tislelizumab. The company also has a preclinical pipeline based on the TSTx technology. In this video, Immix Biopharma’s CEO, Dr Ilya Rachman, provides an overview of the company’s strategy and approach.


You may also be interested in these:

Healthcare

Immix Biopharma – equity proposition

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.